CD274 and neoplasm: Currently, it is believed that especially tumors with a high tumor mutational burden (TMB), PD-L1 expression, or high infiltration of tumor-infiltrating lymphocytes (TILs)—and thus designated as immunologically “hot”—will benefit from immunotherapy [8].